Caladrius Biosciences Inc.

1.62+0.0600+3.85%Vol 718.63K1Y Perf -28.44%
Apr 22nd, 2021 16:00 DELAYED
BID1.61 ASK1.62
Open1.58 Previous Close1.56
Pre-Market1.61 After-Market-
 -0.01 -0.62%  - -
Target Price
8.67 
Analyst Rating
Strong Buy 1.50
Potential %
435.19 
Finscreener Ranking
★★★★+ —    -
Insiders Trans % 3/6/12 mo.
-/-/100 
Value Ranking
★★★★ —    -
Insiders Value % 3/6/12 mo.
-/-/100 
Growth Ranking
★★ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/100 
Income Ranking
 —    -
Market Cap96.39M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
10.16 
Earnings Date
6th May 2021

Today's Price Range

1.561.64

52W Range

1.254.89

5 Year PE Ratio Range

-1.204.70

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
5.88%
1 Month
-18.59%
3 Months
-32.22%
6 Months
-5.26%
1 Year
-28.44%
3 Years
-64.86%
5 Years
-76.18%
10 Years
-99.15%

TickerPriceChg.Chg.%
CLBS1.620.06003.85
AAPL131.94-1.5600-1.17
GOOG2 267.92-25.3700-1.11
MSFT257.17-3.4100-1.31
XOM55.27-0.7300-1.30
WFC42.70-0.5400-1.25
JNJ165.18-1.4100-0.85
FB296.52-4.9500-1.64
GE13.410.06000.45
JPM147.37-3.1700-2.11
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.27-0.28-3.70
Q03 2020-0.30-0.293.33
Q02 2020-0.36-0.338.33
Q01 2020-0.11-0.38-245.45
Q04 2019--0.47-
Q03 2019-0.33-0.47-42.42
Q02 2019-0.44-0.49-11.36
Q01 2019-0.39-0.44-12.82
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.0925.00Positive
6/2021 QR-0.0930.77Positive
12/2021 FY-0.53-1.92Negative
12/2022 FY-0.3326.67Positive
Next Report Date6th May 2021
Estimated EPS Next Report-0.09
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume718.63K
Shares Outstanding59.50M
Trades Count1.95K
Dollar Volume7.62M
Avg. Volume5.52M
Avg. Weekly Volume999.26K
Avg. Monthly Volume1.20M
Avg. Quarterly Volume4.45M

Caladrius Biosciences Inc. (NASDAQ: CLBS) stock closed at 1.62 per share at the end of the most recent trading day (a 3.85% change compared to the prior day closing price) with a volume of 727.18K shares and market capitalization of 96.39M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 27 people. Caladrius Biosciences Inc. CEO is David J. Mazzo.

The one-year performance of Caladrius Biosciences Inc. stock is -28.44%, while year-to-date (YTD) performance is 13.29%. CLBS stock has a five-year performance of -76.18%. Its 52-week range is between 1.25 and 4.89, which gives CLBS stock a 52-week price range ratio of 10.16%

Caladrius Biosciences Inc. currently has a PE ratio of -3.00, a price-to-book (PB) ratio of 2.80, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -24.86%, a ROC of -23.83% and a ROE of -29.55%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Caladrius Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.09 for the next earnings report. Caladrius Biosciences Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Caladrius Biosciences Inc. is Strong Buy (1.5), with a target price of $8.67, which is +435.19% compared to the current price. The earnings rating for Caladrius Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Caladrius Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Caladrius Biosciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 17.72, ATR14 : 0.20, CCI20 : -57.34, Chaikin Money Flow : -0.16, MACD : -0.14, Money Flow Index : 29.86, ROC : -8.99, RSI : 47.94, STOCH (14,3) : 36.17, STOCH RSI : 1.00, UO : 41.02, Williams %R : -63.83), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Caladrius Biosciences Inc. in the last 12-months were: Michael H. Davidson (Buy at a value of $99 945), Michael Harvey Davidson (Buy at a value of $99 945)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
0 (0.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
1 (25.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.25
Strong Buy
1.25

Caladrius Biosciences Inc.

Caladrius Biosciences Inc is a clinical-stage biopharmaceutical company developing cellular therapies designed to reverse, not manage, disease. The company's product candidates include: CLBS119, for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, clinical trial to be initiated in 3Q2020 (USA); CLBS12, recipient of a SAKIGAKE (Japan) and ATMP (Europe) designations, eligible for early conditional approval for the treatment of critical limb ischemia based on an ongoing clinical trial (Japan); CLBS16, subject of the completed proof-of-concept ESCaPE-CMD clinical and planned Phase 2B (U.S.A.); and CLBS14, a Phase 3 ready clinical program in no option refractory disabling angina and recipient of a RMAT designation (USA).

CEO: David J. Mazzo

Telephone: +1 908 842-0100

Address: 110 Allen Road, Basking Ridge 07920, NJ, US

Number of employees: 27

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

60%40%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

News

Stocktwits